Relation of C-2 monitoring with serum lipid profile in stable renal transplant patients

被引:2
作者
Akbas, SH [1 ]
Yurdakonar, E
Yucetin, L
Senol, Y
Tuncer, M
Kocak, H
Akbas, M
Gurkan, A
Demirbas, A
Gultekin, M
机构
[1] Akdeniz Univ, Fac Med, Cent Lab, TR-07070 Antalya, Turkey
[2] Akdeniz Univ, Fac Med, Transplantat Ctr, Antalya, Turkey
[3] Akdeniz Univ, Fac Med, Dept Med Educ, Antalya, Turkey
[4] Akdeniz Univ, Fac Med, Dept Nephrol, Antalya, Turkey
[5] Akdeniz Univ, Fac Med, Dept Anesthesiol, Antalya, Turkey
[6] Akdeniz Univ, Fac Med, Dept Gen Surg, Antalya, Turkey
关键词
D O I
10.1016/j.transproceed.2005.12.088
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
C-2 monitoring has been proposed as a more effective strategy than C-0 to predict the risk of acute rejection in the early stages posttransplantation. However, cyclosporine (CsA) is associated with posttransplant dyslipidemia. The aim of this retrospective study was to evaluate the correlations of GO and C-2 levels with atherogenic risk factors in the first 6 months versus after 6 months posttransplantation. We evaluated the data from 127 stable renal transplant recipients (89 males, 38 females) of mean age 38.10 +/- 12.79 years who received Neoral-based immunosuppression to investigate the relation of C-2 levels to serum lipid profile compared with GO values in the early and late posttransplantation periods. Receiver operating characteristic (ROC) analyses were performed to define a C-2 cutoff level that identified subjects with hypercholesterolemia, defined as a total cholesterol (TC) > 200 mg/dL. There were significant positive correlations between both GO and C-2 levels and TC as well as the ratio of total cholesterol/HDL cholesterol (TC/HDL) in the late period. When the C-2 levels in the late posttransplantation period were stratified, serum TC concentrations showed statistically significant differences between the groups. Whole blood C-2 levels above 850 ng/mL were associated with increased serum TC concentrations; the C-2 cutoff level leading to hypercholesterolemia was 888 ng/mL. Maintenance immunosuppressive therapy under the proposed whole blood C-2 level of 888 ng/mL seemed to preserve graft function while preventing atherogenic risks for cardiovascular diseases in the late posttransplantation period.
引用
收藏
页码:460 / 462
页数:3
相关论文
共 10 条
[1]  
CARDINAL H, 2004, TRANSPLANT P S, V6, pS448
[2]  
DANOVITCH GM, 2001, HDB KIDNEY TRANSPLAN, P62
[3]   A survey to determine the blood concentration of cyclosporine 2 hours postdose in stable renal transplant patients [J].
Jorga, A ;
Holt, DW ;
Yaqoob, M ;
Whittaker, C ;
Johnston, A .
TRANSPLANTATION PROCEEDINGS, 2004, 36 (10) :3239-3241
[4]   Specimen dilution for C2 monitoring with the Abbott TDxFLx cyclosporine monoclonal whole blood assay [J].
Juenke, JM ;
Brown, PI ;
Urry, FM ;
McMillin, GA .
CLINICAL CHEMISTRY, 2004, 50 (08) :1430-1433
[5]  
KASISKE B, 2001, HDB KIDNEY TRANSPLAN, P182
[6]   Two-hour post-dose cyclosporin A levels in adolescent renal transplant recipients in the late post-transplant period [J].
Kavukçu, S ;
Soylu, A ;
Türkmen, M ;
Kasap, B ;
Gümüstekin, M ;
Gülay, H .
PEDIATRIC NEPHROLOGY, 2004, 19 (06) :667-671
[7]   Cardiovascular risk estimates and risk factors in renal transplant recipients [J].
Krämer, BK ;
Böger, C ;
Krüger, B ;
Marienhagen, J ;
Pietrzyk, M ;
Obed, A ;
Paczek, L ;
Mack, M ;
Banas, B .
TRANSPLANTATION PROCEEDINGS, 2005, 37 (04) :1868-1870
[8]   Cyclosporine does not influence serum cholesterol in kidney transplant recipients [J].
Matzkies, FK ;
Keuthage, W ;
Kobelt, V ;
Hillebrand, U ;
Gerhardt, U ;
Suwelack, B ;
Hohage, H .
TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) :1795-1796
[9]  
Sand-Jensen K, 2004, AQUAT ECOL SER, V2, P17
[10]   Cyclosporin A trough levels correlate with serum lipoproteins and apolipoproteins: Implications for therapeutic drug monitoring of cyclosporin A [J].
vonAhsen, N ;
Helmhold, M ;
Schutz, E ;
Eisenhauer, T ;
Armstrong, VW ;
Oellerich, M .
THERAPEUTIC DRUG MONITORING, 1997, 19 (02) :140-145